A narrative review of the principal glucocorticoids employed in cancer

IF 3 3区医学 Q2 ONCOLOGY Seminars in oncology Pub Date : 2022-12-01 DOI:10.1053/j.seminoncol.2023.01.004

Nerina Denaro , Ornella Garrone , Annamaria Morelli , Benedetta Pellegrino , Marco Carlo Merlano , Denise Vacca , Josie Pearce , Daniele Farci , Antonino Musolino , Mario Scartozzi , Chiara Tommasi , Cinzia Solinas

{"title":"A narrative review of the principal glucocorticoids employed in cancer","authors":"Nerina Denaro , Ornella Garrone , Annamaria Morelli , Benedetta Pellegrino , Marco Carlo Merlano , Denise Vacca , Josie Pearce , Daniele Farci , Antonino Musolino , Mario Scartozzi , Chiara Tommasi , Cinzia Solinas","doi":"10.1053/j.seminoncol.2023.01.004","DOIUrl":null,"url":null,"abstract":"<div>Glucocorticoids (GCs) are a pharmacological class of drugs widely used in oncology in both supportive and palliative settings. GCs differentially impact organs with immediate and long-term effects; with suppressive effect on the immune system anchoring their use to manage the toxicities of immune checkpoint inhibitors (ICIs).In addition, GCs are often used in the management of symptoms related to cancer or chemotherapy and as adjuvants in the treatment of pain in the management of other. In the palliative setting, GCs, especially administered subcutaneously can be to assist in the control of nausea, dyspnea, asthenia, and anorexia-cachexia syndrome.In this narrative review, we aim to summarize the role of GCs in the different settings (curative, supportive, and palliative) to help clinicians use these important drugs in their daily clinical practice with cancer patients.</div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775423000040","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glucocorticoids (GCs) are a pharmacological class of drugs widely used in oncology in both supportive and palliative settings. GCs differentially impact organs with immediate and long-term effects; with suppressive effect on the immune system anchoring their use to manage the toxicities of immune checkpoint inhibitors (ICIs).

In addition, GCs are often used in the management of symptoms related to cancer or chemotherapy and as adjuvants in the treatment of pain in the management of other. In the palliative setting, GCs, especially administered subcutaneously can be to assist in the control of nausea, dyspnea, asthenia, and anorexia-cachexia syndrome.

In this narrative review, we aim to summarize the role of GCs in the different settings (curative, supportive, and palliative) to help clinicians use these important drugs in their daily clinical practice with cancer patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

主要糖皮质激素用于癌症的叙述性回顾

糖皮质激素(GCs)是一类广泛应用于肿瘤学支持和姑息治疗的药物。gc对器官的影响不同，有即时和长期影响;对免疫系统具有抑制作用，因此它们被用于控制免疫检查点抑制剂(ICIs)的毒性。此外，GCs通常用于治疗与癌症或化疗相关的症状，并作为辅助治疗其他疾病的疼痛。在姑息治疗中，尤其是皮下注射GCs可帮助控制恶心、呼吸困难、虚弱和厌食症-恶病质综合征。在这篇叙述性综述中，我们旨在总结gc在不同情况下(治疗性、支持性和姑息性)的作用，以帮助临床医生在治疗癌症患者的日常临床实践中使用这些重要的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.

期刊最新文献

Table of Contents Outside front cover Masthead Editorial Board Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer